Inhaled salmeterol/fluticasone propionate: A review of its use in chronic obstructive pulmonary disease

Drugs

Volumn 64, Issue 17, 2004, Pages 1975-1996

  Fenton, Caroline ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MUCOLYTIC AGENT; PLACEBO; RITONAVIR; SALBUTAMOL; SALMETEROL; TETRACOSACTIDE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPNEA; FIRST PASS EFFECT; FORCED EXPIRATORY VOLUME; HEADACHE; HOARSENESS; HUMAN; META ANALYSIS; METERED DOSE INHALER; MONOTHERAPY; MOUTH INFLAMMATION; NAUSEA; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNGITIS; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; THRUSH; TREMOR; VERTIGO; VOMITING;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CLINICAL TRIALS; DRUG COMBINATIONS; HALF-LIFE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

FROG ERYTHROCYTIC VIRUS;

EID: 4644293697     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464170-00014     Document Type: Review

References (79)

1. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease [online]. Available from URL: http://www.thoracic.org/COPD/default.asp [Accessed 2004 Jul 1]
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease updated 2003 [online]. Available from URL: http://www.goidcopd.com/ [Accessed 2004 Apr 16]
3. Agustí AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-60
4. Celli BR, Snider GL, Heffner J, et al., on behalf of the American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995 Nov; 152 (5 Suppl. 2): S77-S120
5. Viegi G. Epidemiology of COPD: a European perspective. Eur Respir J 2003; 22 Suppl. 43: 3s-7s
6. National Heart Lung and Blood Institute. Chronic obstructive pulmonary disease: data fact sheet [online]. Available from URL: http://www.nhlbi.nih.gov/ health/public/lung/other/ copd_fact.pdf [Accessed 2004 Jun 2]
7. World Health Organisation. The World Health Report 2000 [online]. Available from URL: www.who.int/whr2001/2001 [Accessed 2004 Apr 16]
8. GlaxoSmithKline. Advair Diskus 100/50 250/50 500/50 Prescribing Information [online]. Available from URL: http://www.gsk.com/products/advair_us. htm [Accessed 2004 Apr 27]
9. Allen & Hanburys. Seretide 100, 250, 500 Accuhaler [online]. Available from URL: http://:emc.medicines.org.uk [Accessed 2004 Mar 23]
10. Lyseng-Williamson KA, Keating GM. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1 (4): 273-382
11. Pang L, Knox AJ. Synergistic inhibition by beta2-agonists and corticosteroids on tumor necrosis factor (TNF)-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Molec Biol 2000; 23 (1): 79-85
12. Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99-106
13. Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce β2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155: 704-10
14. Kalavantavanich K, Schramm CM. Dexamethasone potentiates high-affinity beta-agonist binding and Gs alpha protein expression in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000 May; 278 (5): L1101-6
15. Eickelberg O, Roth M, Lörx R, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999 Jan 8; 274 (2): 1005-10
16. Piatti G, Ambrosetti U, Dal Sasso M, et al. Effects of salmeterol on ciliary beat and mucus rheology in COPD patients [abstract no. P587]. Eur Respir J 2003 Sep; 22 Suppl. 45: 78s
17. Stewart AG, Harris T, Smallwood DM, et al. Salmeterol and fluticasone propionate synergisticaily inhibit thrombin-stimulated proliferation of human cultured airway fibroblasts [abstract]. Am J Respir Crit Care Med 2001; 163 (5 Suppl. Pt 2): A473
18. Giuliani M, Serpero L, Petecchia L, et al. Inhibitory action of fluticasone propionate (FP) and salmeterol (SAL) on TGF-B-induced expression of a-smooth muscle actin (a-SMA) by human primary airway fibroblasts (Fbs) [abstract no. 191]. ERJ 2003; 22 Suppl. 45: 11S
19. Seeto LJ, Burgess JK, Johnson PR, et al. Effect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2003; 167 (7): A318
20. Chambers CB, Corrigan BW, Newhouse MT. Salmeterol (S) speeds mucociliary transport (MCT) in healthy subjects. Am J Respir Crit Care Med 1999; 159 (3 Suppl. 2): A636
21. Tay HL, Armoogum N, Tan LKS. Nasal mucociliary clearance and salmeterol. Clin Otolaryngol 1997; 22: 68-70
22. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstrucitve pulmonary disease. N Engl J Med 2004 Jun; 350 (26): 2645-53
23. Dowling RB, Johnson M, Cole PJ, et al. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999; 14: 363-9
24. Kanthakumar K., Cundell DR, Johnson M, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol 1994; 112: 493-8
25. Hotchkiss J, Hilaski R, Cho H, et al. Fluticasone propionate attenuates ozone-induced rhinitis and mucous cell metaplasia in rat nasal airway epithelium. Am J Respir Cell Mol Biol 1998; 18: 91-9
26. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90
27. Cazzola M, Santus P, Di Marco F, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003 May; 97 (5): 453-7
28. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995 May; 89: 357-62
29. Santus P, Matera G, Carlucci P, et al. Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD [abstract no. P1847]. Eur Respir J Suppl 2003 Sep; 22 Suppl. 45: 285-6
30. Verhoeven GT, Garrelds IM, Hoogsteden HC, et al. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2001 Feb; 10: 21-6
31. Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996 Feb; 153: 616-21
32. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-6
33. Gizycki MJ, Hattotuwa KL, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002 Sep; 57: 799-803
34. Yildiz F, Kaur AC, Ilgazli A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000; 67: 71-6
35. Ottonello L, Morone P, Dapino P, et al. Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Clin Exp Immunol 1996; 106: 97-102
36. Sekut L, Champion B.R., Page K, et al. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995; 99 (3): 461-6
37. Whelan CJ, Johnson M, Vardey CJ. Comparison of the antiinflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993; 110: 613-8
38. Nials AT, Coleman RA, Johnson M, et al. The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol. Br J Pharmacol 1997; 120: 961-7
39. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781-91
40. Lee DKC, Lipworth BJ. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease. Br J Clin Pharmacol 2004; 57 (4): 388-92
41. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18 (6): 441-72
42. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47 (2): 318-31
43. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42 (5): 895-912
44. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000 Nov; 60 (5): 1207-33
45. Spencer CM, Jarvis B. Salmeterol/fluticasone propionate combination. Drugs 1999 Jun; 57 (6): 933-40
46. Singh SD, Whale C, Hatton A, et al. Comparison of the pharmacokinetics of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease and healthy subjects [abstract]. Am J Rep Crit Care Med 2001; 163 (5 Suppl. Pt 2): A281
47. Mehta R, Barnett V, Kunka RL, et al. Population pharmacokinetics (PK) of fluticasone propionate (FP) in subjects with asthma, COPD and healthy subjects [abstract no. TPII-83]. Clin Pharmacol Ther 2002 Feb; 71 (1): P64. Plus poster presented at the 2002 annual meeting of the American Society for Clinical Pharmacology and Therapeutics; 2002 Mar 24-27; Atlanta
48. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003 Feb 8; 361 (9356): 449-56
49. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 Oct 15; 166: 1084-91
50. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003 Sep; 124 (3): 834-43
51. Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium/ albuterol for the treatment of COPD. Treat Respir Med 2004; 3 (3): 173-81
52. Make BJ, Cicale MJ, Kalberg CJ, et al. A randomized, double-blind trial comparing fluticasone/salmeterol via DISKUS® to ipratropium/albuterol in patients with chronic obstructive pulmonary disease (COPD) [abstract no. C43]. Am J Respir Crit Care Med 2004 May; 169 (7 Suppl.): A597
53. Cazzola M, Noschese P, D'Amato G, et al. Salmeterol/fluticasone propionate in a single inhaler device versus theophylline +FP in patients with COPD [abstract no. P2393]. Eur Respir J Suppl 2002 Sep; 20 Suppl. 38: 386
54. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE Study. Am J Respir Crit Care Med 2002 Nov 15; 166: 1358-63
55. Wouters EFM, Postma DS, Fokkens B, et al. One year withdrawal of fluticasone after three month treatment with combined fluticasone/salmeterol in COPD [abstract no. C22]. Am J Respir Crit Care Med 2004 May; 169 (7 Suppl.): A519
56. Vestbo J, Calverley PMA, Pauwels R, et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract no. P1570]. Eur Respir J 2002 Sep; 20 Suppl. 38: 241
57. Merchant K, Bourne E, Emmett A, et al. Greater improvement in dyspnea with fluticasone propionate/salmeterol 250/50 compared with salmeterol or ipratropium in patients with COPD [abstract no. C22]. Am J Respir Crit Care Med 2004 May; 169 (7 Suppl.): 521
58. Vestbo J, Pauwels R, Calverley PMA, et al. Salmeterol/fluticasone propionate combination produces improvements in lung function detectable within 24 hours in moderate to severe COPD [abstract]. Am J Respir Crit Care Med 2003; 167 (7): A89. Plus poster presented at American Thoracic Society International Conference; 2003 May 16-21; Seattle
59. Calverley P, Pauwels R, Vestbo J, et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD [abstract]. Am J Respir Crit Care Med 2003; 167 (7 Suppl.): A90. Plus poster presented at American Thoracic Society International Conference; 2003 May 16-21; Seattle
60. Bleecker E, Emmett MS, Merchant K, et al. Lung function and symptom improvement with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in albuterol-responsive and non-responsive COPD patients [abstract no. C22]. Am J Respir Crit Care Med 2004 May; 169 (7 Suppl.): A520
61. Davis KJ, Clark D, Knobil K. Inhaled corticosteroid use and risk of non-vertebral fracture among adults with chronic obstructive lung disease in UK general practice. Chest 2003 Oct; 124 Suppl. 4: 166
62. Knobil K, Watkins M, Yates J, et al. Fracture incidence from clinical trials of fluticasone propionate alone or in combination with salmeterol in the treatment of chronic obstructive pulmonary disease. Chest 2002; 122 (4 Suppl.): 43S
63. Prins J, Fokkens B, Jagt PH, et al. COPD and Seretide a Multicentre Intervention and Characterisation (COSMIC) study: rationale and baseline characteristics. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): 905
64. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 May; 161 (5): 1608-13
65. Spencer S, Calverley PMA, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702
66. Seemungal TAR, Donaldson GA, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Resir Crit Care Med 1998; 157: 1418-22
67. Keam SJ, Keating GM. Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3 (4): 247-68
68. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003 Nov; 58 (11): 937-41
69. Spencer S, Calverley PMA, Burge PS, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163 (1): 122-8
70. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998 Mar 14; 351: 773-80
71. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13; 320: 1297-303
72. AstraZeneca. Symbicort prescribing information [online]. Available from URL: http://www.astrazeneca.com [Accessed 2004 Jun 3]
73. Chapman KR. Seretide for obstructive lung disease. Expert Opin Pharmacother 2002; 3 (3): 341-50
74. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
75. Pauwels R, Celli B, Ferguson G, et al. Osteopenia and osteoporosis in patients with chronic obstructive pulmonary disease [abstract no. A109]. Am J Respir Crit Care Med 2003; 167 (7): A235
76. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2 (1): 67-74
77. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002 Oct; 20 (4): 819-25
78. Sturkenboom MCJM. The integrated primary care information experience in COPD in the Netherlands. Eur Respir J 2003; 22 Suppl. 43: 34s-7s
79. The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) Survival Study protocol. Eur Respir J 2004; 24: 206-10